SYRE Earnings Date: Nov 3, 2026 (Estimated) — Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SYRE's next earnings date?
Spyre Therapeutics, Inc. (SYRE) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.78.
How did SYRE do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Spyre Therapeutics, Inc. posted EPS of -$0.36 versus the -$0.74 estimate, a beat of 51.3%. Revenue was $0. The stock's 1-day post-earnings move was -0.6%.
How much does SYRE stock move after earnings?
SYRE beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.8% (up or down) in the day after earnings.
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.74 | -0.36 | +51.35% | $0 | ✅ Beat | -0.56% | -2.10% | -17.05% |
| 2026-05-05 | Q1 2026 | -0.66 | -0.74 | -12.12% | $0 | ❌ Miss | +2.72% | +10.56% | +6.35% |
| 2026-02-19 | Q4 2025 | -0.74 | -0.70 | +5.41% | $0 | ✅ Beat | +14.28% | +14.12% | +9.10% |
| 2025-11-04 | Q3 2025 | -0.72 | -0.15 | +79.17% | $0 | ✅ Beat | -0.57% | +1.61% | +45.82% |
| 2025-08-05 | Q2 2025 | -0.72 | -0.49 | +31.94% | $0 | ✅ Beat | -5.39% | -5.81% | +0.71% |
| 2025-02-27 | Q4 2024 | -0.97 | -0.81 | +16.49% | $0 | ✅ Beat | +7.24% | +11.60% | -2.34% |
| 2024-11-07 | Q3 2024 | -0.83 | -1.36 | -63.86% | $0 | ❌ Miss | +5.00% | -17.03% | -28.87% |
| 2024-08-07 | Q2 2024 | -0.95 | -0.86 | +9.47% | $0 | ✅ Beat | +2.85% | +0.73% | +13.89% |
Showing last 8 quarters.